FAM66A: A Potential Drug Target and Biomarker (G100133172)

Target Name: FAM66A

NCBI ID: G100133172

FAM66A

Other Name(s): Family with sequence similarity 66 member A | family with sequence similarity 66 member A

FAM66A: A Potential Drug Target and Biomarker

FAM66A, also known as SLC30A8, is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The gene is located on chromosome 6 and encodes a protein that is involved in various cellular processes, including cell signaling, DNA replication, and protein transport.

Recent studies have identified FAM66A as a potential drug target due to its involvement in several cellular processes that are associated with the development and progression of various diseases. For example, FAM66A has been shown to be involved in the regulation of cell adhesion, which is critical for the development of cancer cells. Additionally, the protein has been linked to the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases.

FAM66A has also been identified as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that FAM66A levels are elevated in various types of cancer, which could make it a useful biomarker for these diseases. Additionally, the protein has been shown to be involved in the regulation of immune responses, which is critical for the development of autoimmune disorders.

One of the key challenges in studying FAM66A as a drug target and biomarker is its expression and function in different cell types and organisms. However, recent studies have shown that FAM66A can be expressed and activated in a variety of cell types, including cancer cells, neurons, and immune cells.

In addition, several studies have shown that FAM66A can interact with various proteins and drugs, which could be useful for the development of new treatments for these diseases. For example, studies have shown that FAM66A can interact with the drug inhibitor PD-L1, which has been shown to be effective in treating cancer. Additionally, FAM66A has been shown to interact with the protein PD-L1, which is involved in the regulation of immune responses and has been linked to the development of autoimmune disorders.

Overall, FAM66A is a promising drug target and biomarker for a variety of diseases. Further research is needed to fully understand its role in these diseases and to develop new treatments.

Protein Name: Family With Sequence Similarity 66 Member A

The "FAM66A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM66A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.tech.

More Common Targets